Branded

LINCOLN, Calif. — A drug-security product has won a drug-abuse prevention award.

The Locking Cap was named as one of the "Top 5 Technologies to Reduce Prescription Drug Abuse" by the Center for Lawful Access and Abuse Deterrence.

The cap is a four-digit combination-locking lid for prescription medication bottles. The maker of the cap, Cap-n-Lock, launched an updated version of the cap at the beginning of the year to attract the attention of shoppers.

NEW YORK — The state supreme court in Alabama ruled that brand-name drug companies could be sued if patients suffer complications from generic versions of their medicines, according to published reports.

According to The New York Times, an Alabama man named Danny Weeks claimed he developed tardive dyskinesia after taking generic versions of Pfizer's acid reflux drug Reglan (metoclopramide). Pfizer acquired rights to the drug when it bought Wyeth in 2009, and generic drug makers Teva and Actavis, now owned by Watson, make generic versions.

HORSHAM, Pa. — Symphony Health Solutions on Tuesday named Frank Lavelle CEO.  

NEW YORK — While replacing a single combination pill for HIV with generics would save the healthcare system money, it could also diminish the effectiveness of treatment, a new study suggests.

The study, led by investigators at the Massachusetts General Hospital and Weill Cornell Medical College, and published in the Jan. 15 issue of Annals of Internal Medicine, found $1 billion in potential savings, but the more complicated treatment regimen might result in more patients missing doses and a loss of drug effectiveness.

The nation’s highest court has agreed to hear three cases stemming from the longstanding but controversial practice by which branded and generic drug makers agree to delay introduction of a me-too medicine as its brand-name counterpart nears the end of its patent protection. A ruling by the Supreme Court could alter the delicate balance sometimes struck between the two industries as they scramble to either delay or hasten the onset of generic competition for big-selling, patented drugs.

ROCKVILLE, Md. — A maker of drugs for epilepsy has appointed a new executive.

Supernus Pharmaceuticals announced the appointment of Victor Vaughn as SVP sales, a position in which he will be responsible for leading all the company's sales activities.

NEW YORK — Drug maker Otsuka Pharmaceuticals can keep generic versions of its schizophrenia drug off the market, according to published reports.

Bloomberg reported that the Supreme Court upheld a ruling that allowed Otsuka to block Canadian generic drug maker Apotex from marketing a version of the antipsychotic Abilify (aripiprazole), which Otsuka co-markets with Bristol-Myers Squibb.

ATLANTA — Medagate, a wholly owned subsidiary of InComm Holdings, on Monday announced the launch of the MasterCard Dual Value Health Card, the first dual network healthcare spending card. The Dual Value Health Card enables employers and health plans to combine a member/employee healthcare funding purse with a restricted-spend purse for targeted items and incentives.